Amgen Inc (AMGN) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, despite facing market challenges.
Amgen (AMGN) Q4 2024 Earnings Call Transcript
All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speakers' prepared remarks. In order to ensure that everyone has a chance to participate,
AMGN Earnings: Amgen Slips on Soft EPS Guidance
Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter of Fiscal Year
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Merck (MRK) Q4 2024 Earnings Call Transcript
Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter Dannenbaum,
Douglas Emmett, Inc. (DEI) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 5, 2025 2:00 PM ETCompany ParticipantsStuart McElhinney – Vice President
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
FiercePharma15h
With recent launches and more to come, Amgen's biosimilar business is trending up
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
precisionmedicineonline13h
Amgen Reports More Than $2B in Oncology Revenues in Q4
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
Amgen Reports Fourth Quarter And Full Year 2024 Financial Results
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...
Zacks.com on MSN14h
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...
Amgen Q4 Earnings Preview: Street expects revenue to rise more than 8%
Biopharmaceutical company Amgen (AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after ...
Morningstar5d
AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
THOUSAND OAKS, Calif., Jan. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4 ...